In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.

Recent advances in the characterization of the lung cancer genome have suggested that KRAS may frequently be amplified, although little is known regarding the significance of this finding. This is in contrast with activating mutations of KRAS, which occur in approximately 20% of non-small cell lung carcinomas (NSCLCs). We used fluorescence in situ hybridization to provide direct evidence of KRAS amplification for the first time in clinical specimens. We detected amplification in 7 of 100 consecutive NSCLCs, with a concurrent activating KRAS mutation in 4 cases. KRAS amplification was associated with greater expression of p21 as assessed by quantitative immunohistochemical analysis (P = .015). Our data indicate that a sizable subgroup of NSCLCs harbor KRAS amplification, some of which also contain point mutations, and suggest that an increased KRAS copy number may drive p21 overexpression. KRAS amplification may define a unique clinicopathologic subset of NSCLCs with potentially altered responsiveness to targeted therapies.

[1]  M. Meyerson,et al.  TTF1 expression in non‐small cell lung carcinoma: association with TTF1 gene amplification and improved survival , 2009, The Journal of pathology.

[2]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[3]  Francesca Demichelis,et al.  EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.

[4]  V. Seshan,et al.  Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[7]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[8]  I. Chong,et al.  Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing. , 2007, Oncology reports.

[9]  P. Wesseling,et al.  RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations , 2007, Acta Neuropathologica.

[10]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[11]  B. Johansson,et al.  Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer , 2004, Nature Genetics.

[12]  A. Nagy,et al.  Copy number of cancer genes predict tumor grade and survival of pancreatic cancer patients. , 2001, Anticancer research.

[13]  Chi-Hung Lin,et al.  Chromosomal aberrations in nasopharyngeal carcinoma analyzed by comparative genomic hybridization , 1999, Genes, chromosomes & cancer.

[14]  T Takahashi,et al.  Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization , 1999, Genes, chromosomes & cancer.

[15]  T. Ried,et al.  Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice , 1998, Oncogene.

[16]  S. Manoir,et al.  Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. , 1997, Cancer research.

[17]  M. Noguchi,et al.  Amplification of protooncogenes in surgical specimens of human lung carcinomas. , 1989, Cancer research.

[18]  S. Rodenhuis,et al.  Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer. , 1989, British Journal of Cancer.

[19]  J. L. Bos,et al.  A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. , 1986, Nucleic acids research.

[20]  M. Barbacid,et al.  ras gene Amplification and malignant transformation , 1985, Molecular and cellular biology.

[21]  H. Varmus,et al.  A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells , 1983, Nature.

[22]  J. Testa,et al.  Comparative genomic hybridization analysis. , 2002, Methods in molecular medicine.

[23]  A. Nagy,et al.  Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. , 1997, Cancer letters.